ISR Articles

31. Understanding CDMO Selections: Getting It Right 3/25/2022

    Learn the importance of identifying CDMO key decision-makers and exploring how they reach determinations that reshape imprecise product-based marketing into messaging that addresses specific customer concerns.

32. Use Of Preferred Providers Among Small Molecule Outsourcers 3/16/2022

    In Q32021, ISR surveyed outsourcers of small molecule API and outsourcers of small molecule drug product to ask whether their company uses a preferred providers list of contract manufacturers for outsourced manufacturing. The data show use of preferred providers is slightly more common for small molecule API than small molecule drug product manufacturing (56% vs. 51%).

33. Have CDMO Selection Criteria Changed Over The Past Five Years? 3/16/2022

    New relationship dynamics between sponsors and CDMOs contribute to new trends appearing in the outsourced activities and services as well as the way CDMO selection decisions are made. ISR shares how CDMO selection criteria has changed over the past five years and links the attributes to the Life Science Leader’s CDMO Leadership Awards categories.

     
34. Biologic Drug Product Outsourcing Drivers By Company Size 2/14/2022

    The data show that sponsors from large pharma tend to use CMOs to augment internal manufacturing capacity (71%) while sponsors from non-large pharma use CMOs for all manufacturing needs (66%).

35. Small Molecule Drug Substance Outsourcing Drivers by Company Size 2/14/2022

    In Q3 2021, ISR surveyed 124 sponsors who outsource small molecule drug substance manufacturing to learn more about their primary reason for outsourcing. The data show that sponsors from large pharma tend to use CMOs to augment internal manufacturing capacity (66%) while sponsors from non-large pharma use CMOs for all manufacturing needs (58%).

36. What's Happening In Cell & Gene Therapy Development? 2/8/2022

    This ISR report provides support and direction for innovative companies looking to outsource aspects of their cell and gene therapy manufacturing and development through shared research highlights.

37. Small Molecule Drug Substance Pandemic Complications 1/14/2022

    Over the past two years, ISR has asked respondents to its annual small molecule drug substance benchmarking surveys whether they encountered pandemic related complications with their outsourced manufacturing. The data show it was slightly more common for small molecule API outsourcers to experience COVID-19 related manufacturing complications in 2021 than during 2020.

38. Small Molecule Sterile Injectable Outsourcing Volume 11/15/2021

    In Q2 2021, ISR asked 57 respondents how many small molecule sterile injectable products they have on the market, the proportion of sterile injectable manufacturing that is outsourced and the number of CDMOs they use to complete the work. On average, respondents have 3.4 marketed biologic products, of which 67% of drug product manufacturing is outsourced and use an average of 3.3 CDMOs.  To learn how these proportions are predicted to change in the next five years, follow the link to the Sterile Injectable Market Outlook report preview. 

39. Biologic Sterile Injectable Outsourcing Volume 11/15/2021

    On average, respondents have 4.5 marketed biologic products, of which 65% of drug product manufacturing is outsourced. Respondents use an average of 3.3 CDMOs. 

40. Manufacturing Costs For Small Molecule Development Work 10/18/2021

    In Q3 2020, ISR asked 49 respondents to allocate the costs of development work and clinical trial materials for outsourced small molecule drugs. The data show that API Manufacturing and Drug Product Manufacturing and Process Development capture similar proportions of outsourced spend at this stage.